Strand Life Sciences has officially launched South Asia’s first Olink® Explore HT proteomics service, enabling large-scale multi-omics discovery. This advanced platform allows for simultaneous analysis of thousands of proteins from a single sample, supporting deeper insights into disease biology, biomarker discovery, and precision medicine.

As an Olink® Certified Service Provider, Strand can now support the generation of large, multi-modal datasets across diverse and clinically relevant populations in India, broader South Asia, and the Middle East. By integrating proteomics with established strengths in genomics and bioinformatics, Strand is positioned to support global partners in accelerating multiomics research across therapeutic areas such as oncology, nephrology, and metabolic diseases. You can learn more details about this exciting achievement here. 

We had a fantastic experience attending the AACR Annual Meeting 2026 and connecting with researchers, clinicians, and innovators from across the oncology community. The conversations throughout the event highlighted exciting progress in sequencing technologies, scalable variant interpretation, and the growing role of AI and computational methods in oncology research and clinical workflows.

It was inspiring to see the momentum toward more precise, data-driven approaches to cancer research and care. Be sure to check out our resources page to learn more about how our work is helping advance oncology research, and if any of these topics pique your curiosity, we’d love to hear from you!

Thank you to everyone who joined us for another fantastic BayBifx meetup on April 8th! It was an engaging evening filled with insightful talks, lively networking, and thoughtful discussions on how AI and multiomics are shaping precision medicine and clinical genomics. A major highlight was the expert panel discussion, where leaders across industry explored the real-world challenges of validating, integrating, and scaling AI workflows in healthcare and research.

The event recordings are now available on our events page — and if any of the topics spark your curiosity, we’d love to hear from you. Looking forward to the next BayBifx gathering and more great conversations ahead!

We’re excited to launch Strand’s new Agri-Tech webpage, highlighting how our expertise in bioinformatics, AI/ML, genomics, and data science supports next-generation agricultural innovation. Backed by 25 years of scientific experience and a network of 500+ experts, Strand works with organizations across agriculture and animal health to help accelerate R&D, improve biological insights, and build scalable, data-driven solutions. Explore the page to learn more about our capabilities — and if any of these areas spark your curiosity, we’d love to connect! 

We had an amazing time at AMP 2025 in Boston! From presenting our posters on accelerating CRISPR screen data curation and characterizing gene fusions in solid tumors to connecting with the molecular pathology community, the energy throughout the conference was incredible. We loved sharing insights from Strand’s latest R&D, exchanging ideas with researchers, and diving into conversations around CRISPR data, RNA-based NGS testing, and advances in precision oncology. You can check out all our posters on the resource page — and if any topic sparks your curiosity, feel free to reach out. Can’t wait to see everyone at the next AMP! 

Catch the new webinar to see how Strand’s scRNA Portal turns single cell data into clear, actionable research insights. Shrutee Jakhanwal, Associate Director of Product Management at Strand, explains how unified metadata harmonization speeds analysis across single cell datasets. The session includes practical walkthroughs of scRNAseq and PTM pipelines that preserve cellular granularity during integration, and covers automated cell type annotation, perturbation modeling, and drug response prediction to support biomarker discovery. Disease focused examples in IBD and neurodegenerative disorders also offer phenotype level insights and useful takeaways for target discovery, while pointing to potential research avenues.

We had an amazing time at ASHG 2025 in Boston! From sharing novel insights in multi-omics to presenting our posters on Strand’s cutting edge R&D, the energy at Booth 425 was incredible. We loved connecting with researchers, showcasing how data and AI are shaping the future of biology, and diving into topics like PTMs, automating liquid biopsy pipelines, and using UK Biobank data to glean new insights into diseases. You can check out all our posters on the resource page — and if any topic sparks your curiosity, feel free to reach out. Can’t wait to see you all at the next ASHG!

We were very excited to work on a joint case study with Seqera and share how reproducible, cloud ready workflows can support real progress in genomics and precision medicine. In the study, we describe how we use Nextflow and the Seqera Platform to build a consistent and scalable setup for diagnostics and pharma teams. 

The outcome is faster analysis, better use of resources, and clearer genomic insights for diagnostics and pharma teams. We look forward to supporting more teams as they refine and scale their genomic analysis pipelines, and if this interests you, we would love to get in touch!

We are thrilled to share that Strand is now an AWS Select Tier Partner, a milestone shaped by real customer outcomes and a certified team with deep AWS experience. Our work helps teams manage large genomic datasets with secure, scalable platforms, AI driven analysis, and reliable workflows for research and clinical use. This recognition strengthens our focus on practical innovation through AWS, and we look forward to creating more impact together.

We had an awesome time at the BayBifx meetup—great speakers, great food, and even better conversations! The talks were packed with real-world bioinformatics insights, and the energy in the room made the evening truly memorable. Huge thanks to our fantastic speakers, as well as Shane Brubaker, the BayBifx team, and Myriad Genetics for being such generous hosts. If you missed the event but still want to catch up on the talks, head to the events page on the Strand Life Sciences webpage. We’re already looking forward to co-hosting the next meetup in February 2026 — see you there!

We had a great time co-hosting the TriBix meetup with CIRCULOGENE and Mako Medical! The session sparked great conversations around integrating complex bioinformatics for fast, efficient NGS launches — from building resource and time-saving workflows to making platform switches smoother and more scalable. It was a fun, insightful evening with plenty of community connections and stimulating conversations. A huge thanks to everyone who joined us at TriBix. We’re already looking forward to the next meetup and more chances to share ideas!

We had a fantastic time at Bio-IT World 2025, with lively conversations and five poster presentations spanning long-read variant calling, automated single-cell metadata curation, streamlining CNV workflows, using AI and foundation models for target discovery, and Strand’s work in GPU-accelerated epigenetics and fragmentomics. The engaging flow of ideas, technical deep dives, and big-picture discussions left us energized, inspired, and excited for the possibilities ahead. All posters are available on our Resources page — take a look, and if anything sparks your curiosity, we’d love to keep the conversation going.

Celemics and Strand Life Sciences continue to build on a strong partnership to support reliable and efficient NGS analysis through an integrated platform. By combining Celemics target enrichment kits and pipelines with the StrandOmics analysis platform, the teams deliver a smooth sample to report workflow with clinical grade data compliance and regional data support. Over the past two and a half years, this collaboration has enabled fast turnaround and confident variant interpretation across cancer and rare disease cases. We are excited to keep growing together and look forward to supporting more labs worldwide. You can read more about the continued partnership here. 

Our recent webinar on targeted protein degradation is now available on our resource page. In this session, Ashish Kumar Choudhary, Scientist at Strand Life Sciences, talks about proteolysis targeting chimeras or PROTACs and molecular glues, which use ubiquitin proteasome systems for targeted protein degradation and are an emerging therapeutic field. He also discusses why expanding beyond familiar E3 ligases such as CRBN and VHL, and exploring the over 600 types of E3 ligases found in human cells, is important in cancer research. The webinar also shares practical ways to use ligase databases and highlights emerging options such as c10orf90. If this topic sparks your interest, you can also check out this solution snapshot, and reach out to us to continue the conversation.

Palisade Bio has partnered with Strand Life Sciences in an exciting step toward advancing precision medicine for ulcerative colitis (UC). This collaboration brings together Palisade’s rich clinical data from UC studies and Strand’s deep expertise in bioinformatics and biomarker discovery. By combining advanced analytics with real patient insights, the teams aim to improve patient selection and guide targeted therapies linked to PDE4 pathways. It is a meaningful move for both organizations and for the UC community. We are excited about what this partnership can deliver and look forward to the progress ahead. You can read more about this exciting collaboration here. 

We are thrilled to announce that Celemics and Strand Life Sciences have teamed up to deliver an integrated platform for NGS analysis, bringing together strong assay design and trusted bioinformatics expertise. By combining the Celemics pipeline with the StrandOmics analysis platform, the partnership offers a smooth sample to report workflow with built in variant filters and clinical grade data compliance. Customers also benefit from clear data residency options across geographic regions. This collaboration reflects shared experience in genomics and diagnostics and supports faster, reliable reporting. We are excited about the impact of this collaboration for both companies and look forward to what comes next. You can find more details about the collaboration here.